German pharmaceutical company BioNTech, which developed a trailblazing COVID-19 vaccine, will trial a cancer treatment in Britain using the same mRNA technology, the company said on Friday.
German pharmaceutical company BioNTech, which developed a trailblazing COVID-19 vaccine, will trial a cancer treatment in Britain using the same mRNA technology, the company said on Friday.
Comments